Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes
about
Multiple Targets of Salicylic Acid and Its Derivatives in Plants and AnimalsAspirin resistance: an evaluation of current evidence and measurement methodsPersistent platelet activation in patients with type 2 diabetes treated with low doses of aspirinLow-dose aspirin for in vitro fertilization: a systematic review and meta-analysisChronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans.Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cellsAspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Clinical evidence of interaction between clopidogrel and proton pump inhibitorsPlatelet function tests: a comparative review.Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).Pharmacogenomics of platelet responsiveness to aspirin.Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome.Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis.Identifying determinants of variability to tailor aspirin therapy.Optimal aspirin dose in acute coronary syndromes: an emerging consensus.Multidrug Resistance Protein-4 Influences Aspirin Toxicity in Human Cell Line.A critical review of the literature to conduct a toxicity assessment for oral exposure to methyl salicylate.Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery.COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.Absorption and efficacy of acetylsalicylic acid in patients with short bowel syndrome.Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease.Impaired liver cytochrome P450 2C11 activity after dual antiplatelet therapy with aspirin and clopidogrel in rats.Stereoselective Inhibition of Methotrexate Excretion by Glucuronides of Nonsteroidal Anti-inflammatory Drugs via Multidrug Resistance Proteins 2 and 4.
P2860
Q26745979-28AA9654-9867-45CF-BB1F-39B5B2AFC18CQ28183220-65849DFB-B37F-4FB6-A073-E4A590351920Q28219419-930994EC-D3F2-41C2-B0F4-0B64CD2C8A5DQ28220366-E7FA5FAD-3686-41BF-BE9E-BF2363F0FB00Q33387532-EAE5DB51-6150-4021-9F1F-BF0840D1D98EQ34008634-B48AD33B-2953-467E-8A43-F50D49111FB7Q34771381-BDECD5AF-0DBD-4485-B790-8CE0E989474FQ35033722-B48144BF-DF49-40F9-BFBF-5856418FEB91Q35121464-0B3998B5-E10E-4D51-9A5D-102495AB246DQ36248969-AA9F94AD-EA6E-4600-885B-C46FF5BF3821Q36989841-BFCAABC3-8854-408C-8362-CE0290D963A2Q37562830-0F345E62-DFD8-4021-9F6C-6F56DB08215DQ38005318-1AF2A6E2-E553-4859-A21E-5F1403D8C380Q38087384-984672C9-B7A5-4A28-B5B6-1FA7FCB46BE0Q38206844-C22AE25C-3EA3-44EB-B3BB-A8DC38DA0632Q38825961-DE91CD46-A8EA-468C-8541-961CB4AE98C5Q39005117-02C2C0B0-433E-4E5D-8584-3FCE271F315EQ41313656-909C51C2-FE69-4272-8EA9-B2317137FAE5Q42167751-F6250022-43A2-4C34-8FD2-0162A27BB31CQ46061276-4495C168-0440-4263-B041-026C68E608F3Q46480960-DBB6B8AD-4A15-4F43-910C-F827BE618400Q46790430-A24F8D42-5AE9-4581-887A-04A8106A89CBQ50100776-4F008417-7C02-4B41-8060-949F2B908312Q53805550-DABA443E-F328-4C09-B266-D02A2E9ED417
P2860
Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@ast
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@en
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@nl
type
label
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@ast
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@en
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@nl
prefLabel
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@ast
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@en
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@nl
P2093
P921
P3181
P1476
Pharmacokinetic and pharmacody ...... ay affect therapeutic outcomes
@en
P2093
Augusto Di Castelnuovo
Giuseppe Dell'Elba
Nicola Scorpiglione
Romina Pecce
Stefano Manarini
Vincenzo Feliziani
P304
P3181
P356
10.2165/00003088-200342120-00004
P407
P577
2003-01-01T00:00:00Z
P6179
1003800813